Post by Boehringer Ingelheim

#NEWS: This month, we are initiating a global phase III trial in #SystemicSclerosis (SSc), also known as #Scleroderma, investigating our PDE4B inhibitor as potential treatment.     SSc is a progressive, rare autoimmune disease that can affect the skin and internal organs, placing a significant burden on people living with the condition.    Through this trial, we aim to explore whether this investigational medicine could help address the huge unmet need in SSc.    Learn more here 👉 https://lnkd.in/eWm-hHY3 #Rheumatology